DSM Group, the analytical firm, has released a ranking of retail launches based on sales volume in rubles for the period from January to September 2024. The TOP-10 included two drugs promoted by the company “Sotex”.
“Odecromone” ranks fourth among all drugs and first among OTC drugs. This is a drug for the treatment of biliary tract pathologies, which has a combination of selective antispasmodic and choleretic action. The promotion of the brand “Odecromone” is aimed at both a professional audience of doctors (gastroenterologists and therapists) and pharmacists, and at the end consumer.
The “Oddi School” educational project helped “Odekromon” secure second place in prescription rankings across all ATC groups for Q1 2024 (Ipsos Comcon, Prindex Q3 2024). Projects such as “Professionals”, “Pharm Quest”, training cycles at events and in pharmacy chains contribute to increasing the level of knowledge and recommendations among first-line workers. “Odekromon” ranked first in promotional activity among drugs containing hymecromone, according to Ipsos Comcon’s Promo Panel for Q3 2024. In November 2023, the KhimRar group launched “Aviander,” an original drug promoted by Sotex. This is an innovative drug for the treatment of anxiety disorders. The entire drug development cycle, from molecule synthesis to clinical trials and production, takes place in Russia.
“Aviander” entered the TOP-10 launches of 2024 in the retail segment in terms of sales in rubles among all drugs. The drug occupies a leading position in promotional activity among doctors (neurologists, psychiatrists). In less than a year, “Aviander” took the sixth position in prescriptions from neurologists (Ipsos Comcon, Prindex 1-3 quarters of 2024).
